The Patent Finder

Almirall, S.A.

12 patents currently held · Updated Nov 16, 2026
7 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
8
Ending by 2030
Feb 2027
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Nov 28, 2026
    The maintenance fee for Cyclohexylamine derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activities (US 10,300,072) comes due Nov 28, 2026. Unpaid by May 28, 2027, it lapses early.
  • 1 fee due Jul 12, 2027
    The maintenance fee for Cyclohexylamine derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activities (US 9,233,108) comes due Jul 12, 2027. Unpaid by Jan 12, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
PatentTitleStatus Expires Confidence
US 7,875,630Novel Process Salts Compositions and Use
In force
 · High confidence
In forceHigh confidence
US 7,964,615Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the β2 adrenergic receptor
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,044,205Process for manufacturing 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane bromide
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,258,308Amino nicotinic and isonicotinic acid derivatives as DHODH inhibitors
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,085,974Novel Dosage and Formulation
In force
 · Medium confidence
In forceMedium confidence
US 11,000,517Novel Dosage and Formulation
In force
 · Medium confidence
In forceMedium confidence
US 8,865,728Combinations comprising methotrexate and DHODH inhibitors
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,598,363Process for Manufacturing 2-[(3,5-Difluoro-3'-Methoxy-1,1'-Biphenyl-4 Yl)amino]nicotinic Acid
In force
 · High confidence
In forceHigh confidence
US 9,737,520Aclidinium for use in improving the quality of sleep in respiratory patients
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,233,108Cyclohexylamine derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activities
In force
 · From the USPTO record
In forceFrom the USPTO record
10 of 12 patents shown.
Pro members see all 12.
Pro members: see all 12 patents
Also on record, not counted in the 12: 7 patents in force now held by others · 47 lapsed for an unpaid fee · 26 ended at full term · 3 surrendered on reissue. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

2 pending · 7 abandoned · 25 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited